LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Miroli, Augusto"
  2. AU="Stahl, B"
  3. AU="Dehari, Hironari"
  4. AU="Pinheiro, Silviane Bezerra"
  5. AU="Jamal Al Deen Alkoteesh"
  6. AU="Chen, Dingqiang"
  7. AU="Jeremy C. Ganz"
  8. AU="Lee, Ta-Sheng"
  9. AU="Shi, Jin-Ming"
  10. AU=Kristoffersen K B
  11. AU=Du Chao
  12. AU="Anton I. Skaro"

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel ; Online: Inhibidores de Bruton tirosina quinasa ¿qué necesita saber el oncohematólogo y el cardiólogo?

    Baratta, Sergio J / Miroli, Augusto / Pose Cabarcos, Julio / Bezares, Raimundo F

    Medicina

    2023  Band 82, Heft 6, Seite(n) 914–926

    Abstract: Advances in knowledge incorporated in the last decade have modified the treatment paradigm in most of the malignant hematological diseases. In particular, the introduction of Bruton tyrosine kinase inhibitors (BTKi) and other target drugs together with ... ...

    Titelübersetzung Bruton tyrosine kinase inhibitors. What does the oncohematologist and the cardiologist need to know?
    Abstract Advances in knowledge incorporated in the last decade have modified the treatment paradigm in most of the malignant hematological diseases. In particular, the introduction of Bruton tyrosine kinase inhibitors (BTKi) and other target drugs together with new monoclonal antibodies have become agents of choice for both chronic lymphocytic leukemia (CLL) and other peripheral "B" lymphomas such as mantle cell lymphoma (MCL). The results of efficacy against genotoxic therapy are so successful that the end of chemoimmunotherapy, especially for CLL, is already a postulate recognized by the main research groups. On the other hand, the new drugs modified the profile of adverse events, which forced the development of new subspecialties such as cardio-oncology, which currently constitutes a bastion for the rational management of these patients. This review aims to highlight the current state of knowledge on these pathologies, pharmacological principles together with new adverse events of iBTK and the invaluable contribution of cardiology for correct management of these patients.
    Mesh-Begriff(e) Humans ; Adult ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Tyrosine Kinase Inhibitors ; Agammaglobulinaemia Tyrosine Kinase ; Cardiologists ; Lymphoma, Mantle-Cell/drug therapy ; Lymphoma, Mantle-Cell/pathology ; Antineoplastic Agents/adverse effects
    Chemische Substanzen Tyrosine Kinase Inhibitors ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2) ; Antineoplastic Agents
    Sprache Spanisch
    Erscheinungsdatum 2023-01-11
    Erscheinungsland Argentina
    Dokumenttyp Review ; English Abstract ; Journal Article
    ZDB-ID 411586-7
    ISSN 1669-9106 ; 0025-7680 ; 0325-951X
    ISSN (online) 1669-9106
    ISSN 0025-7680 ; 0325-951X
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 163: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: a report from the Argentine Society of Hematology.

    Basquiera, Ana L / García, Mercedes J / Martinez Rolón, Juliana / Olmedo, Julieta / Laviano, Julia / Burgos, Rubén / Caeiro, Gastón / Remaggi, Guillermina / Raña, Pablo / Paoletti, Mariano / González, Carlos M / Fernández, Isolda / Pavlovsky, Astrid / Perusini, Maria A / Rodriguez, Andrea / Guanchiale, Luciana / Carvani, Analia / Mandrile, Laura / Figueroa, Flavia /
    Vicente Reparaz, Angeles / Fragapane Mathus, Patricia N / Garate, Gonzalo / Fauque, María E / Kantor, Gustavo / Cruset, Soledad / Gonzalez Lorch, Jacqueline S / Szelagowski, Milagros / Giarini, María P / Oliveira, Natalia / García, María C / Ventriglia, María V / Pereyra, Patricio H / Gutierrez, Daniel R / Kusminsky, Gustavo / Troccoli, Josefina / Freitas, María J / Cranco, Santiago / Del V Sanchez, Natalia / Rey, Irene / Funes, María E / Jarchum, Sol / Freue, Julian / Miroli, Augusto / Guerrero, Osvaldo / López Ares, Lisa / Campestri, Reinaldo / Bove, Victor / Salinas, Graciela N / Cabrejo, María / Milone, Jorge H / Zabaljauregui, Soledad / Gotta, Daniel / Dupont, Juan Carlos / Stemmelin, German

    Medicina

    2021  Band 81, Heft 4, Seite(n) 536–545

    Abstract: Individuals with malignancies and COVID-19 have a lower survival compared with the general population. However, the information about the impact of COVID-19 on the whole hematological population is scarce. We aimed to describe the 30th day overall ... ...

    Titelübersetzung Características clínicas y evolución de pacientes hematológicos y COVID-19 en Argentina: datos de la Sociedad Argentina de Hematología.
    Abstract Individuals with malignancies and COVID-19 have a lower survival compared with the general population. However, the information about the impact of COVID-19 on the whole hematological population is scarce. We aimed to describe the 30th day overall survival (OS) after COVID-19 infection in patients with a hematological disease in Argentina. A completely anonymous survey from the Argentine Society of Hematology was delivered to all the hematologists in Argentina; it started in April 2020. A cut-off to analyze the data was performed in December 2020 and, finally, 419 patients were reported and suitable for the analysis (average age: 58 years, 90% with malignant diseases). After the COVID-19 diagnosis, the 30-day OS for the whole population was 80.2%. From the entire group (419), 101 (24.1%) individuals required intensive care unit admission, where the 30-day OS was 46.6%. Among allogeneic stem cell transplant recipients, the 30-day OS was 70.3%. Factors associated with a low OS were two or more comorbidities, an active hematological disease and history of chemotherapy. In individuals with the three factors, the 30-day OS was 49.6% while the 30-day OS in those without those factors was 100%. Patients with hematological diseases have a higher mortality than the general population. This group represents a challenge and requires careful decision-making of the treatment in order not to compromise the chances of cure.
    Mesh-Begriff(e) Argentina/epidemiology ; COVID-19 ; COVID-19 Testing ; Hematology ; Humans ; Middle Aged ; SARS-CoV-2
    Sprache Englisch
    Erscheinungsdatum 2021-08-28
    Erscheinungsland Argentina
    Dokumenttyp Journal Article
    ZDB-ID 411586-7
    ISSN 1669-9106 ; 0025-7680 ; 0325-951X
    ISSN (online) 1669-9106
    ISSN 0025-7680 ; 0325-951X
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 163: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang